Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South AfricaResearch in context

Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South AfricaResearch in context

Summary: Background: The integrase strand transfer inhibitor (INSTI) dolutegravir is recommended in World Health Organization guidelines, but is associated with weight gain. We evaluated weight change in patients switching from efavirenz to dolutegravir in first-line antiretroviral therapy (ART) in...

Full description

Bibliographic Details
Main Authors: Alana T. Brennan, Cornelius Nattey, Emma M. Kileel, Sydney Rosen, Mhairi Maskew, Andrew C. Stokes, Matthew P. Fox, Willem D.F. Venter
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:EClinicalMedicine
Subjects:
Integrase strand transfer inhibitors
Dolutegravir
Efavirenz
Weight
Hypertension
South Africa
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023000135

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023000135

Similar Items